Bellevue Life Sciences Acquisition Corp. Files 8-K
Ticker: OSRHW · Form: 8-K · Filed: Sep 24, 2024 · CIK: 1840425
| Field | Detail |
|---|---|
| Company | Bellevue Life Sciences Acquisition Corp. (OSRHW) |
| Form Type | 8-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $11.50, $75,000, $60,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, sec-filing
TL;DR
Bellevue Life Sciences Acquisition Corp. just filed an 8-K, looks like a new deal or financial obligation is in play.
AI Summary
Bellevue Life Sciences Acquisition Corp. entered into a material definitive agreement on September 20, 2024. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The report includes financial statements and exhibits related to these events.
Why It Matters
This 8-K filing signals a significant development for Bellevue Life Sciences Acquisition Corp., potentially involving new financial commitments or agreements that could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — 8-K filings often indicate material events, which can introduce uncertainty or new financial risks for the company.
Key Players & Entities
- Bellevue Life Sciences Acquisition Corp. (company) — Filer
- September 20, 2024 (date) — Earliest event reported
FAQ
What specific material definitive agreement was entered into by Bellevue Life Sciences Acquisition Corp. on September 20, 2024?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on September 20, 2024.
What type of financial obligation is indicated in the 8-K filing?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
What is the SEC file number for this 8-K filing?
The SEC file number is 001-41390.
What is the SIC code for Bellevue Life Sciences Acquisition Corp.?
The Standard Industrial Classification (SIC) code is 3841, for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
When is Bellevue Life Sciences Acquisition Corp.'s fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 885 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-09-24 16:21:30
Key Financial Figures
- $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
- $75,000 — sory Note ") in the principal amount of $75,000 to Jun Chul Whang, a member of the Comp
- $60,000 — sory Note ") in the principal amount of $60,000 to Josh Pan, an individual Member of Be
Filing Documents
- d894329d8k.htm (8-K) — 35KB
- d894329dex101.htm (EX-10.1) — 5KB
- d894329dex102.htm (EX-10.2) — 5KB
- 0001193125-24-224807.txt ( ) — 229KB
- blacu-20240920.xsd (EX-101.SCH) — 5KB
- blacu-20240920_def.xml (EX-101.DEF) — 15KB
- blacu-20240920_lab.xml (EX-101.LAB) — 26KB
- blacu-20240920_pre.xml (EX-101.PRE) — 16KB
- d894329d8k_htm.xml (XML) — 9KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amendment to Promissory Note, dated September 20, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Jun Chul Whang 10.2 Amendment to Promissory Note, dated September 20, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Josh Pan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer